NIH award emphasizes long-term relationship, says AMRI

By Melissa Fassbender contact

- Last updated on GMT

AMRI will support DPI scientists advance early-stage NCATS drug discovery projects. (Image: iStock/Totojang)
AMRI will support DPI scientists advance early-stage NCATS drug discovery projects. (Image: iStock/Totojang)
AMRI has received a 5-year federal contract award from the National Institutes of Health (NIH) under which it will provide drug substance development and manufacturing services.

The award, from NIH’s National Center for Advancing Translational Sciences (NCATS), supports the Division of Pre-Clinical Innovation’s (DPI) drug development programs.

The goal of the DPI is to advance collaborative research projects across pre-clinical phases of the translational science spectrum​,” Chris Conway, senior vice president, discovery, development and analytical services at AMRI told Outsourcing-Pharma.com.

The global contract research and manufacturing organization (CRO) will provide services related to process development, analytical development and small-scale GMP manufacture of small molecule drug candidates for preclinical trials.

Conway explained task order requests for proposals will be circulated amongst all contractors under a particular technical area each time new work is needed.

Investment in additional capacity is not anticipated at this point in time, he said.

The contract emphasizes our long-term relationship with the NIH – we’ve been working with the NIH for years with great success, and we are proud that our relationship with the NIH has grown and matured​,” added Conway.

Related news

Show more

Related products

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers